Methadone death, dosage and torsade de pointes: Risk-benefit policy implications

Journal of Psychoactive Drugs

Volumn 38, Issue 4, 2006, Pages 513-519

  Latowsky, Mark ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Dose; Methadone; Mortality; Policy; Torsade de pointes

Indexed keywords

ALCOHOL; BENZODIAZEPINE; METHADONE; OPIATE;

ADULT; ARTICLE; CANCER PAIN; DEATH; DOSE RESPONSE; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG MEGADOSE; HEALTH CARE POLICY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; METHADONE TREATMENT; OPIATE ADDICTION; QT PROLONGATION; RISK BENEFIT ANALYSIS; SIDE EFFECT; TORSADE DES POINTES; WITHDRAWAL SYNDROME;

EID: 33847362297     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2006.10400590     Document Type: Article

References (119)

1. Anglin, M.D. &McGlothlin, E.H. 1984. Outcome of narcotic addict treatment in California. In: F.M. Tims &J.P. Ludford (Eds) Drug Abuse Treatment Evaluation: Strategies, Progress and Prospects. NIDA Research Monograph 51. Rockville, MD: NIDA.
2. Baden, M.M. 1970. Methadone related deaths in New York City. International Journal of the Addictions 5: 489-98.
3. Bale, R.N.; Van Stone, W.W.; Kulau, J.M.; Engelsing, T.M.J. &Elashoft, R.M. 1980. Therapeutic communities vs. methadone maintenance. A prospective controlled study of narcotic addiction treatment: Design and one year follow up. Archives of General Psychiatry 37: 179-93.
4. Ball, J.C. &Ross, A. 1991. The Effectiveness of Methadone Maintenance. New York: Springer-Verlag.
5. Ball, J.C.; Myers, C.P &Friedman, S.R. 1988. Reducing the risk of AIDS through Methadone Maintenance Treatment. Journal of Health and Social Behavior 29: 214-26.
6. Ballesteros, M.F.; Sanford, C.P; Gilchrist, J.; Agyekem, G.A. &Butts, J. 2003. Increase in deaths due to methadone in North Carolina. Journal of the American Medical Association 290 (1): 40.
7. Barrett, D.H.; Luk, A.J; Parrish, R.G. &Jones, T.S. 1996. An investigation of medical examiner cases in which methadone was detected. Harris County, Texas, 1987-1992. Journal of Forensic Science 41: 442-48.
8. Bednar, M.M.; Harringan, E.P &Ruskin, J.N. 2002. Torsade de pointes associated with non-antiarrhythmic drugs andobservations on gender and QTc. American Journal of Cardiology 89: 1316-19.
9. Bell, J.; Bowron, P; Lewis, J. &Bately, R. 1990 Serumlevels ofmethadone in maintenance clients who persist in illicit drug use. British Journal ofAddiction 85: 1599-1602.
10. Bentley, A.J. &Busuttil A. 1996. Deaths among drug abusers in south-east Scotland, 1989-1994. Meicine, Science and the Law 36: 231-36.
11. Bond, C. 1998. Single nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proceedings of the National Academy of Sciences 95: 9608-13.
12. Blix, O. &Gronbladh, L. 1991. The impact of methadone maintenance treatment on the spread of HIV among IV heroin addicts in Sweden. In: N. Loimer; R. Schmid &A. Springer (Eds) Drug Addiction and AIDS. Vienna: Springer-Verlag.
13. Bryant, W.K.; Galea, S.; Tracey, M.; Markham Piper T. &Tardiff, K.J. 2004. Overdose deaths attributed to methadone and heroin in New York City, 1990-1998. Addiction 99 (7): 846-54.
14. Buster, M.C.; Van Brussel, G.H. &Van Den Brin, W. 2002. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 97(8).
15. Cairns, A.; Roberts, J.S. &Benbow, E.W. 1996. Characteristics of fatal methadone overdose in Manchester, 1985-94. British Medical Journal 313(7052): 264-5.
16. Caplehorn, J R. 1998. Deaths in the first two weeks of maintenance treatment in NSW in 1994: Identifying cases ofiatrogenic methadone toxicity. Drug and Alcohol Review 17: 9-17.
17. Capelhorn, J.R. &Drummer, O.H. 2002. Fatal methadone toxicity: Signs, circumstances, and the role of benzodiazepines. Australia and New Zealand Journal of Public Health 26 (4): 358-63.
18. Capelhorn, J.R. &Drummer, O.H. 1999. Mortality associated with New South Wales methadone programs in 1994: Lives lost and saved. MedicalJournal of Australia 170 (3): 104-9.
19. Capelhorn, J.R. &Bell, J. 1991. Methadone dosage and retention of patients in maintenance treatment. Medical Journal of Australia 54 (3): 195-9.
20. Caplehorn, J.R.; Dalton M.S.; Haldar, F.; Petrenas, A.M. &Nisbet, J.G. 1996. Methadone maintenance and addicts risk of fatal heroin overdose. Substance Use and Misuse 31 (2): 177-96.
21. Cooper, J.R. 1989. Methadone and AIDS. Journal oftheAmerican Medical Association 262: 1664-8.
22. Cooper, J.R.;Altman, F.; Brown, B.S. &Czechowitz, M. 1983. Research on the Treatment of Narcotic Addiction. Washington, D.C.: US GPO.
23. Cooper, G.A.; Seymour, A.; Cassidy, M.T. &Oliver, J.S. 1999. A study of methadone in fatalities in the Strathclyde region, 1991-1996. Medicine, Science andthe Law 39: 233-42.
24. Craig, R.J. 1980. Efectiveness of low dose methadone maintenance for the treatment of inner city heroin addicts. International Journal of the Addictions 15: 701-10.
25. D'aunno, T. &Vaughn, T.F. 1992. Variations in methadone treatment practices: Results from a national study. Journal of the American Medical Association 267: 253-58.
26. Davoli, M.; Perucci, C.A.; Forastire, F.; Doyle, P. &Rapiti, E. 1993. Risk factors for overdose mortality: A case-control study within a cohort of intravenous drug users. International Journal of Epidemiology 22: 273-77.
27. De Bels, D.; Staroukine, M. &Devrienndt, J. 2003. Torsade de pointes due to methadone. Annals of Internal Med 139 (2): E156.
28. Decerf, J.A.; Gressens, B.; Brohet, C.; Liolios, A. &Hantson, P. 2004. Can methadone prolong the QT interval? Intensive Care Medicine 30: 1690-91.
29. Deponti, F.; Poluzzi, E. &Montanaro, N. 2001. Organizing evidence on QT prolongation and occurrence of torsade de pointes with non-arrhythmic drugs: A call for consensus. European Journal of Clinical Pharmacology 57: 185-209.
30. Dole, VP. &Nyswander, M. 1997. Heroin addiction: A metabolic disease. Archives of Internal Medicine 120: 19-24.
31. Dole, V.P. &Nyswander, M. 1995. A medical treatment fordiacetylmorphine (heroin) addiction. Journal of the American Medica/Association 193: 80-84.
32. Dole, V.P.; Robinson, J.W.; Oraaca, J.; Towns, E. &Searcy, P. 1969. Methadone treatment of randomly selected criminal addicts. New England Journal of Medicine 280: 1372-75.
33. Drummer, O.H. &Opeskin, K. 1992. Methadone toxicity causing death in ten subjects starting on a methadone maintenance program. American Journal of Forensic Medicine and Pathology 13 (4): 346-50.
34. Dyer, K.R. &White, J.M. 1997. Patterns of symptom complaints in methadone maintenance patients. Addiction 92 (2): 1445-55.
35. Dyer, K.R.; Foster, D.J.R.; White, J.M.; Somogyi, A.A. &Menelaou, A. 1999. Steady state pharmacokinetics and pharmacodynamics in methadone maintained patients: Comparison of those who do and do not experience withdrawal and concentration-effect relationships. Clinical Pharmacology and Therapeutics 65: 685-94.
36. Dyer, K.R.; White, J.; Foster, D.J.R.; Bochner, F. &Menelaou, A. 2001. The relationship between maood state and plasma methadone concentration in maintenance patients. Journal of Clinical Psychopharmacology 21 (I): 78-84.
37. Eap, C.B.; Bourquin, M.; Martin, J.; Spagnoli, J. &Powell, K. 2000. Plasma concentration of the enantomers of methadone and therapeutic response in methadone maintenance treatment. Drug and Alcohol Dependence 61 (1): 47-54.
38. Eap, C.B.; Bertschy, G.; Finkbeiner, T.; Gastpar, M.; Scherbaum, N. &Baumann, P. 1998. High interindividual variability of methadone enantomer blood levels to dose ratios. Archives of General Psychiatry 55: 89-90.
39. Eap, C.B.; Finkheiner, T.; Gastpar, M.; Scherbaum, N. &Powell, K. 1999. Replacement ofR-Methadone by a double doseofR/S-Methadone in addicts: interindividual variability of the R/S ratios and evidence of adaptive changes in methadone pharmacokinetics. European Journal of Clinical Pharmacology 50: 385-89.
40. Faggiano, F.; Vigna-Taglianti, F.; Veersino, E. &Lemma, P. 2003. Methadone maintenance at different dosages foropioid dependence. Cochrane Database of Systematic Reviews 3: CD002208.
41. Foster, D.J.R.; Somogyi, A.; Dyer, K.R.; White, J.M. &Bochner, F. 2000. Steady state pharmacokinetics of R and S-Methadone in methadone maintenance patients. British Journal of Clinical Pharmacology 50: 427-40.
42. Frank, B. 2000. An overview of heroin trends in New York City: Past, present and future. Journal of Medicine 67 (5-6): 340-46.
43. Fugelstad, A.; Rajs, J.; Bottiger, M. &Gerhardsson de Verrdeir, M. 1995. Mortality among HIV infected intravenous drug addicts in Stockholm in relation to methadone treatment. Addiction 90: 711-16.
44. Gagajewski, A. &Apple, F.S. 2003. Methadone related deaths in Hennepin County, Minnesota: 1992-2002. Journal of Forensic Science 48 (3): 668-71.
45. Gardner, R. 1970. Methadone misuse and death by overdose. British Journal of Addiction 65: 113-18.
46. Gearing, F.R. &Schweitzer, M.D. 1974. An epidemiologic evaluation of long term methadone maintenance treatment for heroin addiction. American Journal of Epidemiology 100: 101-12.
47. Ghodse, H.; Schifano, F.; Oyefeso, A.; Jambert-Gray, R.; Cobain, K. &Cockery, J. 2003. Drug related deaths as reported by participating procurators fiscal and coroners in England, Wales, Northern Ireland, Scotland, Isle of Man, Grumsy, Jersey. In: Annual Review 2002 and NP-SAD Surveillance Report No. II. London: Centre for Addiction Studies, SL George Hospital Medical School.
48. Gil, M.; Sala, M.; Anguera, L.; Chapinal, O. &Cervantes, M. 2003. QT prolongation and torsade de pointes in patient infected with HIV and treated with methadone. American Journal of Cardiology 92: 995-97.
49. Goldstein, A.; Hansteen, R.W. &Horns, W.H. 1975. Control of methadone dosage by patients. Journal of the American Medical Association 234 (7): 734-37.
50. Goodnick, PJ.; Jerry, J. &Parra, F. 2002. Psychotropic drugs and the ECG: Focus on the QT interval. Expert Opinion in Pharmacotherapy 3 (5) 479-98.
51. Grab, H.; Behnsen, S.; Kimont, H.G.; Staak, M. &Kaferstein, H. 2003. Methadone and its role in drug related fatalities in Cologne, 1989-2000 Forensic Science International 132: 195-200.
52. Grabowski, J.G.;Rhoades, H.; Hk, J.S. &Creson, D. 1993. Clinicwide and individualized behavioral interventions in drug dependence treatment. In: L.S. Onken.;J.D. Blaine &J.J. Boren (Eds) Behavioral Treatments for Drug Abuse and Dependence. NIDA Research Monograph # 137. Rockville, MD: U.S. Depart of Health and Human Services.
53. Griffith, C. 2000. Deaths related to drug poisoning: England and Wales, 1998-2002. Health Statistics Quarterly 21: 59-66.
54. Griffith, C.; Brock, A. &Mickleburgh M. 2002. Deaths related to drug poisoning: Results for England and Wales, 1993-2000. Health Statistics Quarterly 13: 76-82.
55. Gronbladh, L.; Ohlund, L.S. &Gunne, L.M. 1990. Mortality in heroin addiction: Impact of methadone treatment. Acta Psychiatrica Scandinavica 82: 223-7.
56. Gunne, L.M. &Gronbladh, L. 1981. The Swedish methadone maintenance program: A controlled study. Drug and Alcohol Dependence 7: 249-56.
57. Havassy, B. &Tschann, J.M. 1983. Client initiative, inertia, and demographics: More powerful than treatment interventions in methadone maintenance. International Journal of the Addictions 18: 617-31.
58. Havassy, B.; Hargreaves, W. &De Barros, L. 1979. Self regulation of dose in methadone maintenance with contingent privileges. Addictive Behaviors 4: 31-38.
59. Haverkamp, W.; Breithardt, G.; Camm, A.J.; Janse, M.J.; Rosen, M.R.; Antzelevitch, C.; Escande, D.; Franz, M.; Malik, M.; Moss, A. &Shah, R. 2000. The potential forQT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Cardiovascular Research 47: 219-33.
60. Hickman, M.; Madden, P.; Baker, A.; Wallace, C. &Wakefield, J. 2003. Trends in drug overdose deaths in England and Wales, 1993-98: Methadone does not kill more people than heroin. Addiction 9: 1325-6.
61. Hiltunen, A.J.; Beck, O.; Hjemdahl, P.; Liljeberg, U. &Almstrom, U.1999. Rated well being in relation to plasma concentrations of L and D-Methadone in satisfied and dissatisfied patients on methadone maintenance treatment. Psychopharmacology 143: 385-93.
62. Holmstrand, J.; Anggard, E. &Gunne, L.M. 1978. Methadone maintenance: plasma levels and therapeutic outcome. Clinical Pharmacology and Therapeutics 23: 175-80.
63. Homes, W.H.; Rado, M. &Goldstein, A. 1975. Plasma levels and symptom complaints in patients maintained on daily dose of methadone hydrochloride. Clinical Pharmacology and Therapeutics 17: 63649.
64. Hubbard, R.L. &Marsden, M.E 1989. DrugAbuse Treatment: A National Study of Effectiveness. Chapel Hill: University of North Carolina Press.
65. Iguchi, M.; Stitzer, M.L.; Bigelow, G.E. &Leibson, I.A. 1988. Contingency management in methadone maintenance: Effects of reinforcing and aversive consequences on illicit polydrug use. Journal of Drug and Alcohol Dependence 22: 1-7.
66. Kidorf, M. &Steizer, M.L. 1996. Contingent use of take homes and split dosing to reduce illicit drug use of methadone patients. Behavior Therapy 27: 41-51.
67. Kornick, C.A.; Kilborne, M.J.; Santiango-Palma, J.; Shulman, G. &Pezzullo, J.C. 2003. QTc interval prolongation associated with intravenous methadone. Pain 105: 499-506.
68. Krantz, M.J. &Mehler, P.S. 2000. Methadone and QT prolongation: A dose dependent effect? American Journal of Cardiology 93 (7): 952.
69. Krantz, M.J.; Rowan, S.B. &Mehler, P.S. 2005. Cocaine related torsade de pointes in a methadone maintenance patient. Journal of Addictive Disease 24 (I): 53-60.
70. Krantz, M.J.; Kutinsky, I. B.; Robertson, A.D. &Mehler, P.S. 2003. Dose related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 23 (6): 802-5.
71. Krantz, M.J.; Lewkowiez, L.; Hays, H.;Woodroffe, M.A.; Robertson, A.D. &Mehler, P.S. 2002. Torsade de pointes associated with very-high dose methadone. Annals of Internal Medicine 137 (6): 501-4.
72. Kreek, M.J. 2000. Methadone related opioid agonist pharmacotherapy for heroin addiction. Annals of the New York Academy of Sciences 909: 186-216.
73. Kreek, M.J. 1973. Plasma and urine levels of methadone. New York State Journal ofMedicine 73: 2773-77.
74. La Harpe, R. &Frye, G. 1995. Todesfalle im Zusammenhang mit methadone-Eiahme im Kanton Genf (1987-1993) Archiv fur Kriminologie 196: 24-29.
75. Leavitt, S B.; Shinderman, M.; Maxwell, S.; Eap, C.B. &Paris, P. 2000. When enough is not enough: New perspectives on optimal methadone maintenance dose. Mount Sinai Journal of Medicine 67 (5-6): 404-11.
76. Lorimer, N. &Schmid, R. 1992. The use of plasma levels to optimize methadone maintenance treatment. Drug and Alcohol Dependence 30: 241-46.
77. Magura S.; Casriel, R.; Goldsmith, D.S.; Strug, D.L. &Lipton, D.S. 1998. Contingency contracting with polydrugabusing methadone patients. Addictive Behaviors 13: 113-18.
78. Man, L.M.; Best, M.; Gossop, M.; Stillwell, G. &Strang, J. 2004. Relationship between prescribing and risk of opiate overdose among drug users in and out of maintenance treatment. European Addiction Research 10 (1): 35-40.
79. Marks, J. 1999 Deaths from methadone and heroin. Lancet 343: 976.
80. Marmor, M; Des Jarlais, D.C. &Cohen, H. 1987. Risk factors for infection of human immunodeficiency virus among intravenous drug abusers in New York City. AIDS I: 39-44.
81. Martell, B.A.;Amsten, J.H.; Ray, B. &Gourevitch, M.N. 2003. The impact of methadone induction on cardiac conduction in opiate users. Annals of Internal Medicine 139 (2): 154-55.
82. Maxwell, S. &Shinderman, M.S. 2002. Optimizing long term response to Methadone MaintenanceTreatmentA 152 week follow up using higher dose methadone. Journal of Addictive Disease 21: 1-12.
83. McGlothlin, W.H. &Anglin, M.D. 1981. Long term follow up of clients of high and low dose methadone programs. Archives of General Psychiatry 38: 1055-63.
84. Milby, J.B.; Carrett, C.; English, C.; Fritschi, O. &Clarke, D. 1978. Take home methadone: Contingency effects on drug seeking and productivity of narcotic addicts. Addictive Behaviors 3: 215-20.
85. Muraskin, W. 1988. The silent epidemic: The social, ethical, and medical problems surrounding the fight against hepatitis. British Journal of Social History 22: 277-98.
86. Neeleman, J. &Ferrell, M. 1997. Fatal methadone and heroin overdose time trends in England and Wales. Journal of Epidemiology and Community Health 51: 435-37.
87. Newcombe, R. 1999. Live and let die: Is methadone more likely to kill you than heroin? Druglink 2: 9-12.
88. Newcome, R. 1996. A reply to Ward. Addiction 91 (II): 1727-29.
89. Newman, R.G. &Whitehell, E.B. 1979. Double blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. CorncetS: 485-88.
90. Pani, P.P., Pirastu, R.; Ricci, A. &Gessa, G.L. 1996. Prohibition of take home dosages: negative consequences on methadone maintenance treatment. Drug and Alcohol Dependence 41: 81-84.
91. Parret, G.; Deglon, J.J.; Kreek, M.J.; Ho, A. &La Harpe, R. 2000. Lethal methadone intoxications in Geneva, Switzerland from 1994-1998. Addiction 95: 1647-53.
92. Patti, A.M.; Santi, A.; Pompa, M.; Giustini, C. &Vescia, N. 1993. Viral hepatitis and drugs: A continuing problem. International Journal of Epidemiology 22: 135-39.
93. Piguet, V.; Desmeules, J.; Ehret, G.; Stoller, R. &Dayer, P. 2004. QT interval prolongation in patients on methadone with concomitant drugs. Journal of Clinical Psychopharmacology 24 (4): 446-48.
94. Pirnay, S.; Borron, S.W.; Giudicelli, C.P.; Tourneau, J. &Baud, F.J. 2004. A critical review of the causes of death among post-mortem toxicological investigations: analysis of34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 99: 978-88.
95. Resnick, R.B. 1977. Problems of methadone diversion and implications for control. International Journal of the Addictions 12: 803-06.
96. Resnick, R.B.; Butler P.; &Washton, A.M. 1981. Patient self adjustment of methadone maintenance dose. In: L. Harris (Ed) Problems of Drug Dependence 1981. NIDA Research Monograph #41. Rockville, MD.: US Dept of Health and Human Services.
97. Rhodes, H.M.; Creson, D.; Elk, R.; Schmitz, J. &Grabowski, J. 1998. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health 88: 34-39.
98. Sala, M.; Anguera, I. &Cervantes, M. 2003. Torsade de pointes due to methadone. Annals oflnternal Medicine 139 (4): W64.
99. Schmitz, J.M.; Rhoades, R.E.; Creson, D.; Hussein, I. &Grobowski, J. 1998. Medication take home doses and contingency management. Experimental and Clinical Psychopharmacology 6 (2): 162-68.
100. Schmoldt, A.; Iwersen-Bergmann, S.; Stein, S.; Franzelius C. &Heinemann, A. 1999. Methadon-Todesfalle und Intoxikationen im Umfeld der Substituierten und bei Drogenkonsimenten. Hamburger Arzteblalt 43: 835-44.
101. Schoenbaum, E.E.; Hartel, D.; Selwyn, P.A.; Klein, R.S. &Davenny K. 1989. Risk factors for human immunodeficiency virus infection in intravenous drug users. New England Journal of Medicine 321: 874-79.
102. Seitzer, M L.; Iguchi, M.Y. &Felch, L.J. 1992. Contingent take home incentive: Effects on drug use of methadone maintenance patients. Journal of Applied Behavior Analysis 15: 493-503.
103. Seitzer, ML.; Iguchi, M.Y.; Kidorf, M. &Bigelow, G.E. 1993. Contingency management in methadone treatment: The case for positive incentives. In: L.S. Onken; J.D. Blaine &J.J. Boren (Eds) Behavioral Treatment for Drug Abuse and Dependence. NIH Pub no. 93-3684: 19-36. Washington,. D.C.: US Dept of Health and Human Services.
104. Senay, E.C. 1985. Methadone maintenance treatment. Internationaljournal of the Addictions 20: 803-21.
105. Seymour, A.; Black, M.;Jay, J.;Cooper, G. &Weir, C. 2003. The role of me^^w in drug related deaths in the west of Scotland. Addiction 98: 995-1002.
106. Strain, E.C.; Biegelow, G.E.; Uebson, I.A. &Steizer, M. 1999. Moderate vs high--dose methadone in the treatment of opioid dependence: A randomized trial. Journal of the American Medical Association 281 (2): 1000-5.
107. Strain, E C.; Steitzer, M L.; Liebson, I.A. &Bigelow, G.E. 1993. Dose response effects of methadone in the treatment of opioid dependence. Annals oflnternal Medicine 119: 23-27.
108. Tennent, F.S.; Rawson, R.A.; Cohen, A.; Tasrver, A. &Clabough D. 1984. Methadone plasma levels and persistent drug abuse in high dose maintenance patients. In: L. Harris (Ed) Probles of Drug Dependence, 1983. NIDA Research Monograph #49. Rockville. MD: NIDA.
109. Tims, F.M. &Ludford, J.P 1984. Drug Abuse Treatment Evaluation: Strategies, Process and Prospects. Rockville, MD: NIDA.
110. Vanichseni, S.; Wongsuwan, B.; Staff of the BMA Narcotics Clinic no. 6; Choopanya, K. &Wongpanich, K.A. 1991. Controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: implications for prevention of HIV. International Journal of the Addictions 26: 1313-20.
111. Vieweg, W.V.R. &Wood, M.A. 2004. Tricyclic antidepressants, QT interval and torsade de pointes. Psychosomatics 45 (5): 371-77.
112. Vincent, G.M. 2000. Long QT Syndrome. Cardiology Clinicsi6: 309-25.
113. Vormfelde, S.V. &Poser, W. 2001. Deaths attributed to methadone. Pharmacopsychiatry 34: 217-22.
114. Walker, P.W.; Klein, D. &Kasza, L. 2003. High dose methadone and ventricular arrhythmias: A report of three cases. Pain 103 (3): 321-24.
115. Ward, J.; Mattick, R.P; Hall, W. &Darke, S. 1996. The effectiveness and safety of methadone maintenance. Addiction 91 (II): 1727-29.
116. Wolff, K.; Sanderson, M;Hay, A.W.M. &Raistrick, D. 1991. Methadone concentration in plasma and their relationship to drug dosage. Clinical Chemistry 37: 205-09.
117. Yankovitz, S.R.; Des Jarlais, D C.; Peyser, N.P; Drew, E &Friedmann P 1991. A randomized trial of an interim methadone maintenance clinic. American Journal of Public Health 81: 1185-91.
118. Zador, D. &Sunjic, S. 2000. Deaths in methadone maintenance treatment in New South Wales Australia, 1990-1995. Addiction 95 (I): 77-84.
119. Zanis, D.A. &Woody, G.E 1998. One-year mortality rates following methadone treatment discharge. Drug and Alcohol Dependence 52 (3): 257-60.